THOUSAND OAKS, Calif.–(BUSINESS WIRE)–Dyve Biosciences, Inc. today announced that longtime Pfizer Executive Chuck Harbert, Ph.D. has joined the company in the role of Chief Scientific Officer.
Dr. Harbert is an acclaimed medicinal chemist and pharmaceutical industry executive with accomplishments spanning three decades with Pfizer. Dr. Harbert held a variety of leadership roles across the drug R&D lifecycle, including Vice President, US Exploratory Development and Strategic Planning, as well as other senior positions at Pfizer Central Research. Dr. Harbert is author or co-author of approximately twenty scientific publications and inventor or co-inventor of approximately thirty-five pharmaceutical patents, including ZOLOFT®. He and other members of the ZOLOFT discovery team received the American Chemical Society Award for Team Innovation.
“Dyve attracted me because they have a breakthrough technology that changes the way drugs are delivered, ultimately improving drug safety and efficacy. Dyve’s scientists have been able to get a broad range of drugs and compounds through the skin with much higher bioavailability, at unprecedented levels, well beyond what I’ve seen in the pharmaceutical industry. I’m excited about the power of the underlying technology and the opportunity to join a very talented team,” said Dr. Harbert.
Ryan Beal, M.D., chief executive officer at Dyve, said: “Chuck’s accomplished tenure at Pfizer is world-class with a stellar track record of translating scientific innovation into clinical and commercial success. He’s been integral to the development of numerous blockbuster drugs and it’s inspiring to be working alongside him. I look forward to working with Chuck, and the rest of the Dyve team, to continue to build this incredible company.”
Dr. Harbert joins following Dyve’s recent announcement that it received FDA clearance to begin its Phase 2 trial of DYV-700, the company’s topically administered therapeutic being developed to reduce the pain and duration of an acute gout flare and the company’s most advanced therapeutic program. Dyve intends to initiate the Phase 2 trial, the TARGETS Study (NCT04130204), in the first quarter of 2020.
About Dyve Biosciences
Dyve Biosciences has developed a breakthrough topical skin penetration technology. The innovative approach enables drugs to be transported from the surface of the skin into the blood with needle-like speed and pill-like efficiency. Dyve has advanced clinical programs in gout and melasma and a robust pre-clinical and clinical data set across a broad set of molecules. At Dyve, the focus is on robust science, compelling data, and delivering positive patient outcomes. For more information please visit dyvebio.com.